Search Thermo Fisher Scientific
Element Search
Structure Search
Thermo Scientific Chemicals
5-Fluorouracil, 99%
5-Fluorouracil, CAS # 51-21-8, is an analogue base composed of uracil with a position 5 hydrogen fluorine substitution.
Have Questions?
Change view
Catalog number 228440010
Price (USD)/ Each
36.65
Online exclusive
43.40 Save 6.75 (16%)
-
Quantity:
1 g
Packaging:
Glass bottle
Price (USD)/ Each
36.65
Online exclusive
43.40 Save 6.75 (16%)
5-Fluorouracil, 99%
Catalog number228440010
Price (USD)/ Each
36.65
Online exclusive
43.40 Save 6.75 (16%)
-
Chemical Identifiers
IUPAC Name5-fluoro-1,2,3,4-tetrahydropyrimidine-2,4-dione
Molecular FormulaC4H3FN2O2
InChI KeyGHASVSINZRGABV-UHFFFAOYSA-N
SMILESFC1=CNC(=O)NC1=O
Molecular Weight (g/mol)130.08
View more
Specifications
Specification Sheet
Specification SheetLoss on drying=<0.5 % (80°C, 4 hrs) (in vacuum)
Infrared spectrumConforms
Titration with NaOH98.5 to 101.0 % (On dried substance)
Heavy metals (as Pb)=<20 ppm
Sulfated ash=<0.1 %
View more
This Thermo Scientific Chemicals brand product was originally part of the Acros Organics product portfolio. Some documentation and label information may refer to the legacy brand. The original Acros Organics product / item code or SKU reference has not changed as a part of the brand transition to Thermo Scientific Chemicals.
General Description
• 5-Fluorouracil is an antimetabolite and antineoplastic that prevents DNA synthesis by blocking conversion of deoxyuridylic acid
• 5-Fluorouracil can replace uracil in RNA and prevent protein synthesis and cell growth
Applications
• 5-Fluorouracil can be used for laboratory research on tumor growth and immunosuppression
• 5-Fluorouracil may also be appropriate for laboratory studies of neurotoxicity, cell lysis, and DNA damage
WARNING: Reproductive Harm - www.P65Warnings.ca.gov
RUO – Research Use Only
General References:
- Kato, K.; Shah, M.A.; Enzinger, P.; Bennouna, J.; Shen, L.; Adenis, A.; Sun, J.M.; Cho, B.C.; Özgüroğlu, M.; Kojima, T.; Kostorov, V.; Hierro, C.; Zhu, Y.; McLean, L.A.; Shah, S.; Doi, T. KEYNOTE-590: Phase III study of first-line chemotherapy with or without pembrolizumab for advanced esophageal cancer. Future Oncol. 2019, (10), 1057-1066.
- Wagner, A.D.; Syn, N.L.; Moehler, M.; Grothe, W.; Yong, W.P.; Tai, B.C.; Ho, J. Unverzagt S. Chemotherapy for advanced gastric cancer. Cochrane Database Syst Rev. 2017, 8(8), CD004064.